Dermatofibrosarcoma protuberans: Neoadjuvant therapy with imatinib mesylate and use of plasma PDGF-B levels to monitor clinical response

Macapinlac, M. P.; Elrafei, Tarek N.; Cunningham, Isabel; Horowitz, Mary M.; Fauzia, P.; Mbaoma, Rowland; Jayabalan, David; Mani, Sridhar

doi:10.1200/jco.2004.22.14_suppl.9049

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To what extent is the varying sensitivity to Imatinib connected to the type of cytogenetic aberration? Is the use of plasma PDGFB levels a real possibility to monitor clinical response (Macapinlac et al 2004)? Is FS-DFSP generally less likely than DFSP to respond?…”

Section: Molecular Targeted Therapy With Imatinibmentioning

confidence: 99%

Current treatment options in dermatofibrosarcoma protuberans

Lemm

Mügge

Mentzel

et al. 2009

J Cancer Res Clin Oncol

217

220

View full text Add to dashboard Cite

Dermatofibrosarcoma protuberans (DFSP) is a rare malignant dermal neoplasm characterized by slow infiltrative growth, little metastatic potential but a high tendency to recur locally after surgical excision. DFSP is associated with a high cure rate. The optimal therapy is complete surgical resection. The recurrence potential of DFSP is directly related to the extent of resection. The need for wide excision margins has been amply documented. Wide local excision is a frequently used practice. Mohs micrographic surgery with continuous histological margin control is further propagated to reduce local recurrence rates. In more than 90% of DFSP, a specific chromosomal aberration is described, involving Chromosomes 17 and 22. It leads to a constitutive activation of the platelet-derived growth factor receptor (PDGFR) followed by continuous stimulation of the tumor cell growth. The use of targeted inhibitors of PDGFR is a good therapeutic option in the treatment strategy of unresectable locally advanced, recurrent or metastatic disease. With Imatinib, a selective PDGFR tyrosin kinase inhibitor, partial and complete remissions of DFSP could be achieved. This article reviews the current opinion and literature about DFSP and resulting therapy strategies.

show abstract

Section: Molecular Targeted Therapy With Imatinibmentioning

confidence: 99%

Current treatment options in dermatofibrosarcoma protuberans

Lemm

Mügge

Mentzel

et al. 2009

J Cancer Res Clin Oncol

217

220

View full text Add to dashboard Cite

show abstract

“…Preclinical studies [97] demonstrated how growth inhibition of dermatofibrosarcoma protuberans could be obtained with the use of imatinib, which acts as an inhibitor of PDGFRB. This paved the way to clinical studies with imatinib [98,99,88], which have also clarified the selective action of imatinib against tumors expressing the t (17:22), with respect to those that did not express it [100].…”

Section: Future Perspectives In the Treatment Of Advanced Soft Tissuementioning

confidence: 96%

“…Imatinib has produced also responses in chemotherapy-resistant locally advanced or metastatic dermatofibrosarcoma protuberans, due to its inhibition of the PDGFR tyrosine kinase. The potential activity of imatinib as neoadjuvant therapy in dermatofibrosarcoma protuberans and the potential value of measuring serial PDGF-B levels to monitor clinical response has been postulated [88]. Imatinib mesylate activity has been observed also in a series of 18 patients with advanced chordoma [89].…”

Section: Imatinibmentioning

confidence: 98%

New emerging drugs in soft tissue sarcoma

Milano

Apice

Ferrari

et al. 2006

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

“…Ebenso existieren noch Fragen zur Möglichkeit des Monitorings des klinischen Ansprechens (PDGFB-Plasmalevel?) [12,47].…”

Section: Wichtig Ist Die Unterscheidung Von 2 Molekularen Subentitätenunclassified

Maligne Bindegewebstumore - Sarkome

Vogt¹,

Körner²,

Müller³

2012

Akt Dermatol

View full text Add to dashboard Cite

Zusammenfassung Malignome der Weichgewebe sind selten. Grunds?tzlich k?nnen jedoch praktisch alle Malignome des Bindegewebes, auch diejenigen, die typischerweise die tieferen Weichteile betreffen, auch einmal dermal oder so oberfl?chlich auftreten, dass der Dermatologe involviert wird in die Diagnostik und Therapie. In der Natur unseres Faches liegt es aber auch, dass der Dermatologe involviert wird bei ?unklaren Schwellungen? der Weichteile. Grundz?ge des Managements der Weichgewebetumoren im Allgemeinen sollten daher bekannt sein, da der Dermatologe unter Umst?nden wesentlich zur Verk?rzung des oft zu langen pr?diagnostischen Intervalls beitragen kann. Daneben gibt es f?r den Dermatologen auch zahlenm??ig relevante Entit?ten (Dermatofibrosarkoma protuberans, Leiomyosarkom, atypisches Fibroxanthom), sowie solche, die aggressiv und klinisch-differenzialdiagnostisch wichtig sind, wenn auch selten (Angiosarkom, epitheloides Sarkom), und es gibt auch versteckte Restrisiken, an die gedacht werden sollte, z.?B. ein Neurofibrosarkom auf dem Boden einer langj?hrigen Neurofibromatose oder ?bertherapie einer nodul?ren Fasciitis, eines Pseudosarkoms. Diese Aspekte werden ihrer klinischen Bedeutung entsprechend in diesem Artikel behandelt.

show abstract

Dermatofibrosarcoma protuberans: Neoadjuvant therapy with imatinib mesylate and use of plasma PDGF-B levels to monitor clinical response

Cited by 4 publications

References 0 publications

Current treatment options in dermatofibrosarcoma protuberans

Current treatment options in dermatofibrosarcoma protuberans

New emerging drugs in soft tissue sarcoma

Maligne Bindegewebstumore - Sarkome

Contact Info

Product

Resources

About